A 100 percent protection treatment against the Ebola virus has been found by SAB Biotherapeutics, Inc, a USD Discovery District anchor tenant.
The clinical biopharmaceutical company was recognized in a study published in The Journal of Infectious Diseases.
Rich Naser, Jr., USD Discovery District president said that SAB Biotherapeutics is “cutting edge” in a news release from the university.
“SAB Biotherapeutics is on the cutting edge of biotherapeutics with their novel immunotherapy platform,” Naser said, “This is the kind of groundbreaking science we aim to foster in the Discovery District to provide opportunities for students, researchers and faculty.”
In June, the company announced that it will have it will have its corporate headquarters, research laboratories and cGMP biomanufacturing suite in the USD Discovery District, the news release said.
“We’re excited to provide the physical assets for these innovative emerging companies; we’re more excited to provide the workforce they need to keep growing,” Naser said. “The university is responding with new programs and certifications. In areas such as biomedical engineering, regulatory affairs and CGMP manufacturing, these companies need to bring new innovations and make a greater impact.”